Journal
CURRENT OPINION IN RHEUMATOLOGY
Volume 21, Issue 2, Pages 143-149Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/BOR.0b013e328325bd94
Keywords
allopurinol; benzbromarone; febuxostat; probenecid; puricase
Categories
Ask authors/readers for more resources
Purpose of review To discuss currently available urate-lowering therapeutic options for gout in the United States and newer therapeutic initiatives in development. Recent findings Currently available urate-lowering drugs include allopurinol and probenecid. These drugs are effective but are often underdosed or underutilized, and caution must be taken in patients with multiple comorbidities. Newer therapeutic agents in development include febuxostat, a nonpurine analogue xanthine oxidase inhibitor, and pegloticase, a pegylated recombinant uricase. Summary There have been no new US Food and Drug Administration-approved urate-lowering drugs for gout in the past 40 years. Recent advances in therapeutics promise to provide the opportunity for much needed improvement in patient outcomes in this disorder.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available